Medindia

X

Johnson & Johnson Reports Fourth-Quarter and Full-Year 2007 Results

Tuesday, January 22, 2008 General News J E 4
Advertisement
NEW BRUNSWICK, N.J., Jan. 22 Johnson & Johnsontoday announced record sales of $16.0 billion for the fourth quarter of 2007,an increase of 16.6% as compared to the fourth quarter of 2006. Operationalgrowth was 11.9% and currency contributed 4.7%. Domestic sales were up 9.1%,while international sales increased 25.8%, reflecting operational growth of15.3% and a positive currency impact of 10.5%. Worldwide sales for the year2007 were $61.1 billion, an increase of 14.6% over 2006. Operational growthwas 11.5% with currency contributing 3.1%. On a proforma basis, including thenet impact of the acquisition of Pfizer Consumer Healthcare in both periods,worldwide sales increased operationally 4.6% and 4.2% for the fourth-quarterand full-year 2007, respectively.

Net earnings and diluted earnings per share for the fourth quarter of 2007were $2.4 billion and $.82 respectively, representing increases of 9.5% and10.8% respectively, compared to the same period in 2006. Net earnings for thefourth quarter of 2007 included an after-tax, non-cash charge of $441 millionfor the write-down of the intangible asset related to NATRECOR (nesiritide)and a tax gain of $267 million associated with the restructuring of certaininternational subsidiaries. Net earnings for the fourth quarter of 2006included an after-tax charge for in-process research and development of $217million associated with the acquisition of Pfizer Consumer Healthcare.Excluding these special items, 2007 fourth-quarter net earnings were $2.5billion and earnings per share were $.88, representing increases of 6.8% and8.6%, respectively, as compared with the same period in 2006. *

Net earnings and diluted earnings per share for the year, as reported,were $10.6 billion and $3.63, decreases of 4.3% and 2.7%, respectively, ascompared with 2006. Full-year 2007 net earnings included after-tax charges of$807 million for in-process research and development; $528 million forrestructuring; an after-tax, non-cash charge of $441 million for the write-down of the intangible asset related to NATRECOR (nesiritide); and a gain of$267 million for international tax restructuring. Full-year 2006 net earningsincluded after-tax charges for in-process research and development of $448million and an after-tax gain of $368 million associated with the terminationof the Guidant acquisition agreement. Excluding these special items, netearnings for 2007 were $12.1 billion and earnings per share were $4.15,representing increases of 8.6% and 10.4%, respectively, as compared with thesame period in 2006. * The Company announced its earnings guidance for full-year 2008 of $4.39 to $4.44 per share, which excludes the impact of in-processresearch and development charges or other special items.

"Despite challenges in certain markets, our broad base of businessesallowed us to achieve solid results in 2007, building on our foundation oflong-term profitable growth," said William C. Weldon, Chairman and ChiefExecutive Officer. "It was a year of significant progress in our pipeline; thesuccessful integration of Pfizer Consumer Healthcare; and the creation of neworganizational structures focused on future growth."

Worldwide, the Medical Devices and Diagnostics segment achieved annualsales of $21.7 billion in 2007, representing an increase over the prior yearof 7.2% with operational growth of 3.9% and a positive currency impact of3.3%. Domestic sales increased 3.2%, while international sales increased 11.1%(4.6% from operations and 6.5% from currency).

Primary contributors to the operational growth included Vistakon'sdisposable contact lenses; LifeScan's blood glucose monitoring and insulindelivery products; Ethicon Endo-Surgery's minimally invasive products; DePuy'sorthopaedic joint reconstruction and sports medicine businesses; Ortho-Clinical Diagnostics' professional products; and Ethicon's wound care andwomen's health products. G
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Stryker Issues Statement Regarding FDA Warning Let...
S
KV Pharmaceutical Company Announces Acquisition of...